Combination of photodynamic therapy and temozolomide on glioma in a rat C6 glioma model

Photodiagnosis and Photodynamic Therapy

Volumn 11, Issue 4, 2014, Pages 603-612

  Zhang, Xiaoming ^a   Guo, Mian ^a   Shen, Lei ^b   Hu, Shaoshan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

Blood tumor barrier; Glioma; P glycoprotein; Photodynamic therapy; Temozolomide

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; SODIUM CHLORIDE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; HEMATOPORPHYRIN; HEMATOPORPHYRIN MONOMETHYL ETHER; PHOTOSENSITIZING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER SIZE; CELL DEATH; ENDOTHELIUM CELL; GLIOMA; GLIOMA CELL; GLIOMA CELL LINE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; LOW LEVEL LASER THERAPY; MALE; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; SURVIVAL; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; THERAPY EFFECT; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT DURATION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DRUG COMBINATION; PATHOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; RAT; TREATMENT OUTCOME; TUMOR CELL LINE; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DRUG THERAPY, COMBINATION; GLIOMA; HEMATOPORPHYRINS; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84918779384     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2014.10.007     Document Type: Article

References (68)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Carpentier A.F. Neuro-oncology: the growing role of chemotherapy in glioma. Lancet Neurol 2005, 4:4-5.
3. Schinkel A.H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999, 36:179-194.
4. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
5. Newlands E.S., Blackledge G.R., Slack J.A., Rustin G.J., Smith D.B., Stuart N.S., et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992, 65:287-291.
6. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
7. Drablos F., Feyzi E., Aas P.A., Vaagbo C.B., Kavli B., Bratlie M.S., et al. Alkylation damage in DNA and RNA - repair mechanisms and medical significance. DNA Repair (Amst) 2004, 3:1389-1407.
8. Wedge S.R., Newlands E.S. O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer 1996, 73:1049-1052.
9. Wedge S.R., Porteous J.K., Newlands E.S. 3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996, 74:1030-1036.
10. Wedge S.R., Porteus J.K., May B.L., Newlands E.S. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br J Cancer 1996, 73:482-490.
11. Roos W.P., Batista L.F., Naumann S.C., Wick W., Weller M., Menck C.F., et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007, 26:186-197.
12. Patel M., McCully C., Godwin K., Balis F.M. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 2003, 61:203-207.
13. Bradshaw T.D., Stone E.L., Trapani V., Leong C.O., Matthews C.S., te Poele R., et al. Mechanisms of acquired resistance to 2-(4-amino-3-methylphenyl)benzothiazole in breast cancer cell lines. Breast Cancer Res Treat 2008, 110:57-68.
14. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J Pathol 2005, 205:275-292.
15. Shi X., Liu S., Kleeff J., Friess H., Buchler M.W. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002, 62:354-362.
16. Schaich M., Kestel L., Pfirrmann M., Robel K., Illmer T., Kramer M., et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol 2009, 20:175-181.
17. Benyahia B., Huguet S., Decleves X., Mokhtari K., Criniere E., Bernaudin J.F., et al. Multidrug resistance-associated protein MRP1 expression in human gliomas: chemosensitization to vincristine and etoposide by indomethacin in human glioma cell lines overexpressing MRP1. J Neurooncol 2004, 66:65-70.
18. Popovic E.A., Kaye A.H., Hill J.S. Photodynamic therapy of brain tumors. Semin Surg Oncol 1995, 11:335-345.
19. Nowis D., Stokłosa T., Legat M., Issat T., Jakóbisiak M., Golqb J., et al. The influence of photodynamic therapy on the immune response. Photodiagn Photodyn Therapy 2005, 2:283-298.
20. Muller P.J., Wilson B.C. Photodynamic therapy for recurrent supratentorial gliomas. Semin Surg Oncol 1995, 11:346-354.
21. Origitano T.C., Caron M.J., Reichman O.H. Photodynamic therapy for intracranial neoplasms. Literature review and institutional experience. Mol Chem Neuropathol 1994, 21:337-352.
22. Schmidt M.H., Meyer G.A., Reichert K.W., Cheng J., Krouwer H.G., et al. Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. J Neurooncol 2004, 67:201-207.
23. Whelan H.T. High-grade glioma/glioblastoma multiforme: is there a role for photodynamic therapy?. J Natl Compr Canc Netw 2012, 10(Suppl. 2):S31-S34.
24. Hill J.S., Kaye A.H., Sawyer W.H., Morstyn G., Megison P.D., Stylli S.S. Selective uptake of hematoporphyrin derivative into human cerebral glioma. Neurosurgery 1990, 26:248-254.
25. Hoober J.K., Sery T.W., Yamamoto N. Photodynamic sensitizers from chlorophyll: purpurin-18 and chlorin p6. Photochem Photobiol 1988, 48:579-582.
26. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat Rev Cancer 2003, 3:380-387.
27. Li P., Sun J.G., Huang C.R., Pan G.Y., Xu M.J., Li J., et al. Development and validation of a sensitive quantification method for hematoporphyrin monomethyl ether in plasma using high-performance liquid chromatography with fluorescence detection. Biomed Chromatogr 2006, 20:1277-1282.
28. Song K., Kong B., Qu X., Li L., Yang Q. Phototoxicity of Hemoporfin to ovarian cancer. Biochem Biophys Res Commun 2005, 337:127-132.
29. Ding X., Xu Q., Liu F., Zhou P., Gu Y., Zeng J., et al. Hematoporphyrin monomethyl ether photodynamic damage on HeLa cells by means of reactive oxygen species production and cytosolic free calcium concentration elevation. Cancer Lett 2004, 216:43-54.
30. Gu Y., Huang N.Y., Liang J., Pan Y.M., Liu F.G. Clinical study of 1949 cases of port wine stains treated with vascular photodynamic therapy (Gu's PDT). Ann Dermatol Venereol 2007, 134:241-244.
31. Yuan K.H., Li Q., Yu W.L., Zeng D., Zhang C., Huang Z. Comparison of photodynamic therapy and pulsed dye laser in patients with port wine stain birthmarks: a retrospective analysis. Photodiagn Photodyn Ther 2008, 5:50-57.
32. Tang P.M., Zhang D.M., Xuan N.H., Tsui S.K., Waye M.M., Kong S.K., et al. Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. Mol Cancer 2009, 8:56.
33. Sato Y., Yamazaki T., Yasukawa K., Kaneita Y., Mochimaru J., Hanai M., et al. Merocyanine 540-mediated photodynamic therapy inhibits P-glycoprotein (P-gp) activity in adriamycin-resistant K562 cells. Gan To Kagaku Ryoho 1999, 26:2195-2200.
34. Zhan Q., Yue W., Shaoshan H. The inhibitory effect of photodynamic therapy and of an anti-VCAM-1 monoclonal antibody on the in vivo growth of C6 glioma xenografts. Braz J Med Biol Res 2011, 44:489-490.
35. Zhang X., Cong D., Shen D., Gao X., Chen L., Hu S. The effect of bumetanide on photodynamic therapy-induced peri-tumor edema of C6 glioma xenografts. Lasers Surg Med 2014, 46:422-430.
36. Song D., Yue W., Li Z., Li J., Zhao J., Zhang N. Study of the mechanism of sonodynamic therapy in a rat glioma model. OncoTargets Ther 2014, 7:1801-1810.
37. Tian Z., Quan X., Xu C., Dan L., Guo H., Leung W. Hematoporphyrin monomethyl ether enhances the killing action of ultrasound on osteosarcoma in vivo. J Ultrasound Med 2009, 28:1695-1702.
38. Tsang L.L., Quarterman C.P., Gescher A., Slack J.A. Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide. Cancer Chemother Pharmacol 1991, 27:342-346.
39. Fiore D., Jackson A.J., Didolkar M.S., Dandu V.R. Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-pressure liquid chromatography. Antimicrob Agents Chemother 1985, 27:977-979.
40. Cheng J., Liang H., Li Q., Peng C., Li Z., Shi S., et al. Hematoporphyrin monomethyl ether-mediated photodynamic effects on THP-1 cell-derived macrophages. J Photochem Photobiol B 2010, 101:9-15.
41. Omuro A., DeAngelis L.M. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013, 310:1842-1850.
42. Zhang J., Stevens M.F., Bradshaw T.D. Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 2012, 5:102-114.
43. Lin J.H., Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003, 42:59-98.
44. Hetzel F.W., Brahmavar S.M., Chen Q., Jacques S.L., Patterson M.S., Wilson B.C., et al. AAPM Report No. 88, Photodynamic therapy dosimetry 2005.
45. Huang Z., Xu H., Meyers A.D., Musani A.I., Wang L., Tagg R., et al. Photodynamic therapy for treatment of solid tumors - potential and technical challenges. Technol Cancer Res Treat 2008, 7:309-320.
46. Wilson B.C., Patterson M.S., Lilge L. Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci 1997, 12:182-199.
47. Zeng H., Sun M., Zhou C., Yin F., Wang Z., Hua Y., et al. Hematoporphyrin monomethyl ether-mediated photodynamic therapy selectively kills sarcomas by inducing apoptosis. PLOS ONE 2013, 8:e77727.
48. Stylli S.S., Kaye A.H., MacGregor L., Howes M., Rajendra P. Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci 2005, 12:389-398.
49. Eljamel M.S. New light on the brain: the role of photosensitizing agents and laser light in the management of invasive intracranial tumors. Technol Cancer Res Treat 2003, 2:303-309.
50. Almeida R.D., Manadas B.J., Carvalho A.P., Duarte C.B. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004, 1704:59-86.
51. Wyld L., Reed M.W., Brown N.J. Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br J Cancer 2001, 84:1384-1386.
52. Vantieghem A., Assefa Z., Vandenabeele P., Declercq W., Courtois S., Vandenheede J., et al. Hypericin-induced photosensitization of HeLa cells leads to apoptosis or necrosis. Involvement of cytochrome c and procaspase-3 activation in the mechanism of apoptosis. FEBS Lett 1998, 440:19-24.
53. Plaetzer K., Kiesslich T., Krammer B., Hammerl P. Characterization of the cell death modes and the associated changes in cellular energy supply in response to AlPcS4-PDT. Photochem Photobiol Sci 2002, 1:172-177.
54. Moan J., Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991, 53:549-553.
55. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., et al. Photodynamic therapy. J Natl Cancer Inst 1998, 90:889-905.
56. Kessel D., Reiners J.J. Apoptosis and autophagy after mitochondrial or endoplasmic reticulum photodamage. Photochem Photobiol 2007, 83:1024-1028.
57. Kessel D., Vicente M.G., Reiners J.J. Initiation of apoptosis and autophagy by photodynamic therapy. Lasers Surg Med 2006, 38:482-488.
58. Chen B., Pogue B.W., Hoopes P.J., Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr 2006, 16:279-305.
59. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res 2001, 21:4271-4277.
60. O'Connor A.E., Gallagher W.M., Byrne A.T. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 2009, 85:1053-1074.
61. Molinari A., Bombelli C., Mannino S., Stringaro A., Toccacieli L., Calcabrini A., et al. m-THPC-mediated photodynamic therapy of malignant gliomas: assessment of a new transfection strategy. Int J Cancer 2007, 121:1149-1155.
62. Obwegeser A., Jakober R., Kostron H. Uptake and kinetics of 14C-labelled meta-tetrahydroxyphenylchlorin and 5-aminolaevulinic acid in the C6 rat glioma model. Br J Cancer 1998, 78:733-738.
63. Zimmermann A., Ritsch-Marte M., Kostron H. mTHPC-mediated photodynamic diagnosis of malignant brain tumors. Photochem Photobiol 2001, 74:611-616.
64. Pandey R.K. Recent advances in photodynamic therapy. J Porphyrins Phthalocyanines 2000, 4:368-373.
65. Ali-Seyed M., Bhuvaneswari R., Soo K.C., Olivo M. Photolon - photosensitization induces apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes. Int J Oncol 2011, 39:821-831.
66. Wachowska M., Muchowicz A., Firczuk M., Gabrysiak M., Winiarska M., Wanczyk M., et al. Aminolevulinic acid (ALA) as a prodrug in photodynamic therapy of cancer. Molecules 2011, 16:4140-4164.
67. Li H.T., Song X.Y., Yang C., Li Q., Tang D., Tian W.R., et al. Effect of hematoporphyrin monomethyl ether-mediated PDT on the mitochondria of canine breast cancer cells. Photodiagnosis Photodyn Ther 2013, 10:414-421.
68. Zhan Q., Yue W., Hu S. Effect of photodynamic therapy and endostatin on human glioma xenografts in nude mice. Photodiagnosis Photodyn Ther 2011, 8:314-320.